Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.69USD
16 Jul 2019
Change (% chg)

$-0.26 (-6.58%)
Prev Close
$3.95
Open
$3.96
Day's High
$3.99
Day's Low
$3.66
Volume
1,323,925
Avg. Vol
1,242,450
52-wk High
$18.50
52-wk Low
$3.54

About

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $893.42
Shares Outstanding(Mil.): 226.18
Dividend: --
Yield (%): --

Financials

  ENDP.OQ Industry Sector
P/E (TTM): -- 30.33 34.23
EPS (TTM): -2.10 -- --
ROI: -5.57 12.99 12.65
ROE: -- 14.18 17.19

Endo gains on favorable FDA drug compounding decision

Endo International Plc said on Friday the U.S. health regulator has decided https://bit.ly/2XGrm1k not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version of the product.

01 Mar 2019

Endo gains on favorable FDA drug compounding decision

March 1 Endo International Plc said on Friday the U.S. health regulator has decided https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm632432.htm?utm_campaign=Compounding:%20FDA%20finalizes%20guidance%20on%20evaluating%20the%20clinical%20need%20for%20outsourcing&utm_medium=email&utm_source=Eloqua not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version of the produ

01 Mar 2019

Earnings vs. Estimates